Pharsight

Glumetza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7780987 SANTARUS INC Controlled release dosage forms
Mar, 2025

(1 year, 5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8323692 SANTARUS INC Controlled release dosage forms
Mar, 2023

(5 months ago)

Glumetza is owned by Santarus Inc.

Glumetza contains Metformin Hydrochloride.

Glumetza has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Glumetza are:

  • US8323692

Glumetza was authorised for market use on 03 June, 2005.

Glumetza is available in tablet, extended release;oral dosage forms.

The generics of Glumetza are possible to be released after 23 March, 2025.

Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 03 June, 2005

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of GLUMETZA before it's drug patent expiration?
More Information on Dosage

GLUMETZA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic